Citation

Kalechstein AD, De La Garza R, Mahoney JJ, Fantegrossi WE, Newton TF. Psychopharmacology 2007; 189(4): 531-537.

Affiliation

Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at the University of California, Los Angeles, CA 90024, USA. adk@ucla.edu

Copyright

(Copyright © 2007, Holtzbrinck Springer Nature Publishing Group)

DOI

10.1007/s00213-006-0601-2

PMID

17082969

Abstract

RATIONALE: To determine the association between MDMA misuse and neurocognition using meta-analysis. OBJECTIVE: Separate analyses were conducted based on two sets of inclusion/exclusion criteria. A relatively stringent set required that the subjects be matched on important moderator variables, whereas the other did not. The study participants' performance in the following neurocognitive domains was reviewed: attention/concentration, verbal and nonverbal learning and memory, psychomotor speed and executive systems functioning. RESULTS: In the 11 studies meeting the relatively stringent inclusion/exclusion criteria for this review, MDMA use was associated with neurocognitive deficits in each domain. Similarly, in the 23 studies meeting the relatively lenient inclusion/exclusion criteria for this review, MDMA use was associated with neurocognitive deficits in each domain. Small to medium effect sizes were generally observed. A comparison of the effect sizes across the two sets of analyses did not reveal significant differences. CONCLUSIONS: The findings from this review reveal that MDMA use is associated with neurocognitive deficits. The implications of these findings are discussed.

Language: en